Chip Baird News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Food and Drug Administration approved Abecma for adults with relapsed or refractory multiple myeloma who have received two or more previous lines of therapy.

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety...

By Colin Kellaher 2seventy bio has agreed to sell its research-and-development pipeline to Regeneron Pharmaceuticals as part of a pivot by the biotechnology company to focus exclusively on the...

The company on Tuesday also named Chief Operating Officer Chip Baird as its new chief executive, while current CEO Nick Leschly takes over the duties of chairman. Activist investor Engine Capital, in December, urged for a board refresh at the company and insisted for exclusive focus on Abecma. Both the cell therapies work by collecting white blood cells from a patient, genetically modifying them to fight a cancer and then infusing them back into the patient.

- Company to focus exclusively on commercialization and development of Abecma, in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell...